Brasil
 
O conteúdo desse portal pode ser acessível em Libras usando o VLibras

Arctium lappa L. (Asteraceae): a promising therapy against Covid-19

    Lorena Cotta Repolês

    Dynamic College of Vale do Piranga (FADIP), School of Medicine, Rua G, 205, Paraíso, CEP 35430-324. Ponte Nova, MG, Brazil

    Industrial Pharmacist graduated from Centro Universitário Newton Paiva (2010) with Specialization in Clinical Pharmacology from Associação Mineira de Farmacêuticos (2012). She is currently a medical student at Faculdade Dinâmica do Vale do Piranga-FADIP. In the professional market, she was Technical Responsible at the establishments of Drogaria Araujo, Clínica Odontológica, GastroCenter, LD Cosmetics Distributor and Industrial Planning Analyst at Bio Extratus Cosmeticos Naturais. She was a professor of Education in Health and Safety and Health at the National Program for Access to Technical Education and Employment at the Federal Institute of Minas Gerais-IFMG. Persistent, responsible and organized. She has the ability to absorb new knowledge and work in a team.

    Bruna Soares de Souza Lima Rodrigues

    Dynamic College of Vale do Piranga (FADIP), School of Medicine, Rua G, 205, Paraíso, CEP 35430-324. Ponte Nova, MG, Brazil

    Graduated in Biological Sciences from the Pontifical Catholic University of Minas Gerias (PUC-MInas) (2009). Master (2013) and Doctor (2017) in Parasitology from the Federal University of Minas Gerais (UFMG). She is currently a Full Professor at the School of Medicine and in the Physiotherapy, Pharmacy, Nursing, Nutrition courses at Faculdade Dinâmica da Vale do Piranga (FADIP). Permanent Professor of the Postgraduate Program in Education, Health and Environment (PROCISA) and member of the Animal Research Ethics Committee (CEUA) at the same institution. She works in orientation projects in the area of Parasitology in the following programs: Centers for Studies in Medical Sciences (NUMED) and Applied Education Program (PEA).

Keywords

Abstract

Abstract                                                                

The Covid-19 etiology was identified by scientists in January 2020 after pneumonia cases occurred in China in December 2019. Considered a puzzle for medicine and a worldwide challenge to public health, the disease presents a high transmission speed. Infections may be asymptomatic, or with variable symptomatology, and may in severe cases progress to death. In the hospital phase, intravenous remdesivir and dhimshasone oral or intravenous showed positive results, but there is no scientific evidence about a specific treatment validated at the early stage. The bardana (Arctium lappa Linne) presents actions related to the inhibition of viral replication, antioxidant action, modulation of important cytokines such as TNF-α, IL-6, IL-1β, and IL-10 and inhibition of NF-κB pathway activation; which could favor a balanced inflammatory response. An integrative literature review was carried out in the Database of PubMed® (Public/Publisher Medline) using the descriptor Arctium lappa, from 2005 to 2021. It resulted, in 29 articles, the anti-inflammatory, antiviral, immunomodulatory and/or antioxidant effects of arctigenin and arctiin, present in this plant. These findings point to the possibility of therapeutic use of these compounds, in the initial symptomatological phase of Covid-19, considering the pathophysiology of the disease.

References

  1. Barbosa IR, Galvão MHR, Souza TA, Gomes SM, Medeiros A A, Lima KC. Incidence of and mortality from COVID-19 in the older Brazilian population and its relationship with contextual indicators: an ecological study. Rev Bras Geriatr e Gerontol. 2020; 23(1). ISSN 1981-2256. [CrossRef].
  2. Bezerra CB, Saintrain MVL, Braga DRA, Santos FS, Lima AOP, Brito EHS et al. Impacto psicossocial do isolamento durante pandemia de covid-19 na população brasileira: análise transversal preliminar. Saúde Soc. 2020; 29(4): 1-10. ISSN 1984-0470. [CrossRef].
  3. Brasil MS. Boletim Epidemiológico Especial. Semana Epidemiológica 8 (21 a 27/2/2021) [Internet]. Brasília - DF: Secretaria de Vilgilância em Saúde, Ministério da Saúde; 2021. [Link].
  4. De Amorim MB, Araújo DN, Fernandes Bezerra E, Elaine M, Araruna C. Aspecctos farmacológicos, terapias propostas e cuidados farmacêuticos no contexto da COVID-19. J Biol Pharm Agric Manag. 2021; 17(2). ISSN 1983-4209. [Link].
  5. Brasil MS. Protocolo de Manejo Clínico da Covid-19 na Atenção Especializada [Internet]. 1st ed. Brasilia - DF: Ministério da Saúde, Secretaria de Atenção Especializada à Saúde, Departamento de Atenção Hospitalar, Domiciliar e de Urgência. 2020. [Link].
  6. Jain V, Yuan J-M. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. Int J Public Health. 2020; 65(5): 533-46. ISSN 1661-8556. [CrossRef].
  7. Tomazini BM, Maia IS, Bueno FR, Silva MVAO, Baldassare FP, Costa ELV et al. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomized trial. Rev Bras Ter Intensiva. 2020; 32(3): 354-62. ISSN 0103-507X. [CrossRef].
  8. Ramlall V, Thangaraj PM, Meydan C, Foox J, Butler D, Kim J et al. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat Med. 2020; 26(10): 1609-15. ISSN 1078-8956. [CrossRef].
  9. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020; 383(19): 1813-26. ISSN 0028-4793. [CrossRef].
  10. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021; 384(8): 693-704. ISSN 0028-4793. [CrossRef].
  11. Sterne JAC, Murthy S, Diaz J V, Slutsky AS, Villar J, Angus DC et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020; 324(13): 1330. ISSN 0098-7484. [CrossRef].
  12. Lima AR, Barbosa VC, Santos Filho PR, Gouvêa CMCP. Avaliação in vitro da atividade antioxidante do extrato hidroalcoólico de folhas de bardana. Rev Bras Farmacogn. 2006; 16(4): 531-6. ISSN 0102-695X. [CrossRef].
  13. Gao Q, Yang M, Zuo Z. Overview of the anti-inflammatory effects, pharmacokinetic properties and clinical efficacies of arctigenin and arctiin from Arctium lappa L.. Acta Pharmacol Sin. 2018; 39(5): 787-801. ISSN 1671-4083. [CrossRef].
  14. Predes FS, Ruiz ALTG, Carvalho JE, Foglio MA, Dolder H. Antioxidative and in vitro antiproliferative activity of Arctium lappa root extracts. BMC Complement Altern Med. 2011; 11(1): 1-5. ISSN 1472-6882. [CrossRef].
  15. Gadotti AC, Lipinski AL, Vasconcellos FT, Marqueze LF, Cunha EB, Campos AC et al. Susceptibility of the patients infected with Sars-Cov2 to oxidative stress and possible interplay with severity of the disease. Free Radic Biol Med. 2021; 165: 184-90. ISSN 0891-5849. [CrossRef].
  16. Schröder HC, Merz H, Steffen R, Müller WEG, Sarin PS, Trumm S et al. Differential in vitro Anti-HIV activity of natural lignans. Zeitschrift für Naturforsch C. 1990; 45(11-12): 1215-21. ISSN 1865-7125. [CrossRef].
  17. Swarup V, Ghosh J, Mishra MK, Basu A. Novel strategy for treatment of Japanese encephalitis using arctigenin, a plant lignan. J Antimicrob Chemother. 2008; 61(3): 679-88. ISSN 0305-7453. [CrossRef].
  18. Yang Z, Liu N, Huang B, Wang Y, Hu Y, Zhu Y. Effect of anti-influenza virus of Arctigenin in vivo. Zhong Yao Cai. 2005; 28(11): 1012-4. ISSN 1001-4454. [Link]
  19. Park SY, Hong SS, Han XH, Hwang JS, Lee D, Ro JS et al. Lignans from Arctium lappa and their inhibition of LPS-induced nitric oxide production. Chem Pharm Bull. 2007; 55(1): 150-2. ISSN 0009-2363. [CrossRef].
  20. Zhao J, Chen Y, Dong L, Li X, Dong R, Zhou D et al. Arctigenin protects mice from thioglycollateâ€induced acute peritonitis. Pharmacol Res Perspect. 2020; 8(5). ISSN 2052-1707. [CrossRef]
  21. Hayashi K, Narutaki K, Nagaoka Y, Hayashi T, Uesato S. Therapeutic Effect of Arctiin and Arctigenin in Immunocompetent and Immunocompromised Mice Infected with Influenza A Virus. Biol Pharm Bull. 2010; 33(7): 1199-205. ISSN 0918-6158. [CrossRef]
  22. . Huang T-C. Effect of Arctium lappa L. in the dextran sulfate sodium colitis mouse model. World J Gastroenterol. 2010; 16(33): 4193. ISSN 1007-9327. [CrossRef].
  23. Tsai W-J, Chang C-T, Wang G-J, Lee T-H, Chang S-F, Lu S-C et al. Arctigenin from Arctium lappa inhibits interleukin-2 and interferon gene expression in primary human T lymphocytes. Chin Med. 2011;6(1): 12. ISSN 1749-8546. [CrossRef].
  24. Fan T, Jiang WL, Zhu J, Feng Zhang Y. Arctigenin protects focal cerebral ischemia-reperfusion rats through inhibiting neuroinflammation. Biol Pharm Bull. 2012; 35(11): 2004-9. ISSN 0918-6158. [CrossRef].
  25. Hyam SR, Lee I-A, Gu W, Kim K-A, Jeong J-J, Jang S-E et al. Arctigenin ameliorates inflammation in vitro and in vivo by inhibiting the PI3K/AKT pathway and polarizing M1 macrophages to M2-like macrophages. Eur J Pharmacol. 2013; 708(1-3): 21-9. ISSN 0014-2999. [CrossRef].
  26. da Silva LM, Allemand A, Mendes DAGB, dos Santos AC, André E, de Souza LM et al. Ethanolic extract of roots from Arctium lappa L. accelerates the healing of acetic acid-induced gastric ulcer in rats: Involvement of the antioxidant system. Food Chem Toxicol. 2013; 51(1): 179-87. ISSN 02786915. [CrossRef].
  27. de Almeida ABA, Sánchez-Hidalgo M, Martín AR, Luiz-Ferreira A, Trigo JR, Vilegas W et al. Anti-inflammatory intestinal activity of Arctium lappa L. (Asteraceae) in TNBS colitis model. J Ethnopharmacol. 2013; 146(1): 300-10. ISSN 0378-8741. [CrossRef].
  28. Liu W, Wang J, Zhang Z, Xu J, Xie Z, Slavin M et al. In vitro and in vivo antioxidant activity of a fructan from the roots of Arctium lappa L. Int J Biol Macromol. 2014; 65: 446-53. ISSN 01418130. [CrossRef].
  29. Colitti M, Pomari E, Stefanon B. Effect of plant extracts on H2O2-induced inflammatory gene expression in macrophages. J Inflamm Res. 2014; 7(1): 103. ISSN 1178-7031. [CrossRef].
  30. Tian X, Sui S, Huang J, Bai J-P, Ren T-S, Zhao Q-C. Neuroprotective effects of Arctium lappa L. roots against glutamate-induced oxidative stress by inhibiting phosphorylation of p38, JNK and ERK 1/2 MAPKs in PC12 cells. Environ Toxicol Pharmacol. 2014; 38(1): 189-98. ISSN 13826689. [CrossRef].
  31. Maghsoumi-Norouzabad L, Alipoor B, Abed R, Eftekhar Sadat B, Mesgari-Abbasi M, Asghari Jafarabadi M. Effects of Arctium lappa L. (Burdock) root tea on inflammatory status and oxidative stress in patients with knee osteoarthritis. Int J Rheum Dis. 2016; 19(3): 255-61. ISSN 17561841. [CrossRef].
  32. Wu X, Yang Y, Dou Y, Ye J, Bian D, Wei Z et al. Arctigenin but not arctiin acts as the major effective constituent of Arctium lappa L. fruit for attenuating colonic inflammatory response induced by dextran sulfate sodium in mice. Int Immunopharmacol. 2014; 23(2): 505-15. ISSN 15675769. [CrossRef].
  33. Chen J, Li W, Jin E, He Q, Yan W, Yang H et al. The antiviral activity of arctigenin in traditional Chinese medicine on porcine circovirus type 2. Res Vet Sci. 2016; 106: 159-64. ISSN 0034-5288. [CrossRef].
  34. Dias MM, Zuza O, Riani LR, de Faria Pinto P, Pinto PLS, Silva MP et al. In vitro schistosomicidal and antiviral activities of Arctium lappa L. (Asteraceae) against Schistosoma mansoni and Herpes simplex virus-1. Biomed Pharmacother. 2017; 94: 489-98. ISSN 0753-3322. [CrossRef].
  35. Kim Y-K, Koppula S, Shim D-W, In E-J, Kwak S-B, Kim M-K et al. Inhibitory Effect and Mechanism of Arctium lappa Extract on NLRP3 Inflammasome Activation. Evidence-Based Complement Altern Med. 2018 jan 18; 2018: 1-10. ISSN 1741-427X. [CrossRef].
  36. Lu Z, Chang L, Du Q, Huang Y, Zhang X, Wu X et al. Arctigenin Induces an Activation Response in Porcine Alveolar Macrophage Through TLR6-NOX2-MAPKs Signaling Pathway. Front Pharmacol. 2018; 9(MAY). ISSN 1663-9812. [CrossRef].
  37. Zhou B, Weng G, Huang Z, Liu T, Dai F. Arctiin Prevents LPS-Induced Acute Lung Injury via Inhibition of PI3K/AKT Signaling Pathway in Mice. Inflammation. 2018; 41(6): 2129-35. ISSN 0360-3997. [CrossRef].
  38. Gurunanselage Don RAS, Yap MKK. Arctium lappa L. root extract induces cell death via mitochondrial-mediated caspase-dependent apoptosis in Jurkat human leukemic T cells. Biomed Pharmacother. 2019; 110: 918-29. ISSN 07533322. [CrossRef].
  39. Wang Y, Zhang N, Kan J, Zhang X, Wu X, Sun R et al. Structural characterization of water-soluble polysaccharide from Arctium lappa and its effects on colitis mice. Carbohydr Polym. 2019; 213: 89-99. ISSN 0144-8617. [CrossRef].
  40. Nascimento BAC, Gardinassi LG, Silveira IMG, Gallucci MG, Tomé MA, Oliveira JFD et al. Arctium lappa extract suppresses inflammation and inhibits melanoma progression. Medicines. 2019; 6(3): 81. ISSN 2305-6320. [CrossRef].
  41. Zhang N, Wang Y, Kan J, Wu X, Zhang X, Tang S et al. In vivo and in vitro anti-inflammatory effects of water-soluble polysaccharide from Arctium lappa. Int J Biol Macromol. 2019; 135: 717-24. ISSN 01418130. [CrossRef].
  42. Alhusaini A, Fadda L, Hasan IH, Ali HM, El Orabi NF, Badr AM et al. Arctium lappa root extract prevents lead-induced liver injury by attenuating oxidative stress and inflammation, and activating Akt/GSK-3β signaling. Antioxidants. 2019; 8(12). ISSN 2076-3921. [CrossRef][PubMed].
  43. Kim D, Choi Y, Shim J, Choi Y-S, Kim Y, Kim M et al. Suppressive Effect of Arctium Lappa L. Leaves on Retinal Damage Against A2E-Induced ARPE-19 Cells and Mice. Molecules. 2020; 25(7): 1737. ISSN 1420-3049. [CrossRef] [PubMed].
  44. Zhao F, Wang L, Liu K. In vitro anti-inflammatory effects of arctigenin, a lignan from Arctium lappa L., through inhibition on iNOS pathway. J Ethnopharmacol. 2009; 122(3): 457-62. ISSN 03788741. [CrossRef].
  45. Bavia L, Dias Fontana P, Bovo F, Souza ARC, Corazza ML, Messiasâ€Reason IJ. Inhibitory Effect of Supercritical Extracts from Arctium lappa L. on the Lectin Pathway of the Complement System. Chem Biodivers. 2019; 16(12): e1900401. ISSN 1612-1872. [CrossRef]
  46. El Khatib N, Morel S, Hugon G, Rapior S, Carnac G, Saint N. Identification of a Sesquiterpene Lactone from Arctium lappa Leaves with Antioxidant Activity in Primary Human Muscle Cells. Molecules. 2021; 26(5): 1328. ISSN 1420-3049. [CrossRef]
  47. Samprathi M, Jayashree M. Biomarkers in COVID-19: an up-to-date review. Front Pediatr. 2021; 8: 607-647. ISSN 2296-2360. [CrossRef]
  48. Barbosa KBF, Costa NMB, Alfenas R de CG, De Paula SO, Minim VPR, Bressan J. Estresse oxidativo: conceito, implicações e fatores modulatórios. Rev Nutr. 2010; 23(4): 629-43. ISSN 1415-5273. [CrossRef].
  49. Chernyak BV, Popova EN, Prikhodko AS, Grebenchikov OA, Zinovkina LA, Zinovkin RA. COVID-19 and Oxidative Stress. Biochem. 2020; 85(12-13): 1543-53. ISSN 0006-2979. [CrossRef].
  50. Flambó DFALP. Atividades biológicas dos flavonoides: atividade antimicrobiana. 43f. Porto. 2013. Dissertação de Mestrado [em Ciências Farmacêuticas] - Faculdade de Ciências da Saúde. Universidade Fernando Pessoa, UFP, Porto, Portugal. 2013. [CrossRef]
  51. Oliveira VP de, Espeschit ACR, Peluzio M do CG. Flavonoides e doenças cardiovasculares: ação antioxidante. RMMG - Rev Méd MG. Out/Dez 2006; 16(4): 234-8. ISSN 2238-3182. [CrossRef].
  52. Sant’Ana Dusse LM, Vieira LM, Carvalho M das G. Revisão sobre óxido nítrico Nitric oxide revision. J Bras Patol e Med Lab. 2003; 39(4): 3430-50. ISSN 0102-8650. [CrossRef].
  53. Sautebin L, Ialenti A, Ianaro A, Di Rosa M. Endogenous nitric oxide increases prostaglandin biosynthesis in carrageenin rat paw oedema. Eur J Pharmacol. 1995; 286(2): 219-22. ISSN 0014-2999. [CrossRef].
  54. Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F et al. Complement as a target in COVID-19? Nat Rev Immunol. 2020; 20(6): 343-4. ISSN 1474-1733. [CrossRef].
PDF (Portuguese)
HTML (Portuguese)
XML (Portuguese)
Save bookmark

Author(s)

  • Lorena Cotta Repolês
    Dynamic College of Vale do Piranga (FADIP), School of Medicine, Rua G, 205, Paraíso, CEP 35430-324. Ponte Nova, MG, Brazil
  • Bruna Soares de Souza Lima Rodrigues
    Dynamic College of Vale do Piranga (FADIP), School of Medicine, Rua G, 205, Paraíso, CEP 35430-324. Ponte Nova, MG, Brazil

Metrics

  • Article viewed 597 time(s)

How to Cite

1.
Arctium lappa L. (Asteraceae): a promising therapy against Covid-19. Rev Fitos [Internet]. 2021 Dec. 17 [cited 2025 Apr. 17];15(4):508-22. Available from: https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1242
Crossref
Scopus
Google Scholar
Europe PMC

1. DIREITOS CEDIDOS - A cessão total não exclusiva, permanente e irrevogável dos direitos autorais patrimoniais não comerciais de utilização de que trata este documento inclui, exemplificativamente, os direitos de disponibilização e comunicação pública da OBRA, em qualquer meio ou veículo, inclusive em Repositórios Digitais, bem como os direitos de reprodução, exibição, execução, declamação, recitação, exposição, arquivamento, inclusão em banco de dados, preservação, difusão, distribuição, divulgação, empréstimo, tradução, dublagem, legendagem, inclusão em novas obras ou coletâneas, reutilização, edição, produção de material didático e cursos ou qualquer forma de utilização não comercial.

2. AUTORIZAÇÃO A TERCEIROS - A cessão aqui especificada concede à FIOCRUZ - FUNDAÇÃO OSWALDO CRUZ o direito de autorizar qualquer pessoa – física ou jurídica, pública ou privada, nacional ou estrangeira – a acessar e utilizar amplamente a OBRA, sem exclusividade, para quaisquer finalidades não comerciais, nos termos deste instrumento.

3. USOS NÃO COMERCIAIS - Usos não comerciais são aqueles em que a OBRA é disponibilizada gratuitamente, sem cobrança ao usuário e sem intuito de lucro direto por parte daquele que a disponibiliza e utiliza.

4. NÃO EXCLUSIVIDADE - A não exclusividade dos direitos cedidos significa que tanto o AUTOR como a FIOCRUZ - FUNDAÇÃO OSWALDO CRUZ ou seus autorizados poderão exercê-los individualmente de forma independente de autorização ou comunicação, prévia ou futura.

5. DIREITOS RESERVADOS - São reservados exclusivamente ao(s) AUTOR(es) os direitos morais sobre as obras de sua autoria e/ou titularidade, sendo os terceiros usuários responsáveis pela atribuição de autoria e manutenção da integridade da OBRA em qualquer utilização. Ficam reservados exclusivamente ao(s) AUTOR(es) e/ou TITULAR(es) os usos comerciais da OBRA incluída no âmbito deste instrumento.

6. AUTORIA E TITULARIDADE - O AUTOR declara ainda que a obra é criação original própria e inédita, responsabilizando-se integralmente pelo conteúdo e outros elementos que fazem parte da OBRA, inclusive os direitos de voz e imagem vinculados à OBRA, obrigando-se a indenizar terceiros por danos, bem como indenizar e ressarcir a FIOCRUZ - FUNDAÇÃO OSWALDO CRUZ de eventuais despesas que vierem a suportar, em razão de qualquer ofensa a direitos autorais ou direitos de voz ou imagem, principalmente no que diz respeito a plágio e violações de direitos.

7. GRATUIDADE - A cessão e autorização dos direitos indicados e estabelecidos neste Instrumento será gratuita, não sendo devida qualquer remuneração, a qualquer título, ao autor e/ou titular, a qualquer tempo.

Report an error
Conteúdo acessível em Libras usando o VLibras Widget com opções dos Avatares Ícaro, Hosana ou Guga. Conteúdo acessível em Libras usando o VLibras Widget com opções dos Avatares Ícaro, Hosana ou Guga.